ADCendo ApS seeks to explore novel targets in development of antibody-drug conjugates, to create new anti-cancer medicine for patients with a significant unmet need. The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen. The company is funded by a EUR 51M series a, completed in April 2021.ADCendo ApS is a resident company at Bioinnovation Institute (BII).